Interpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining

Similar documents
The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas. W Glenn McCluggage Belfast, Northern Ireland

Current Concept in Ovarian Carcinoma: Pathology Perspectives

Case 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno

Epithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer?

of 20 to 80 and subsequently declines [2].

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer

Disclosure. Objectives

5/26/2016. Pelvic Serous Carcinoma: 2014 W.H.O. Update. Outline of Talk. Changes to 2014 WHO system for pelvic serous tumors

Ovarian carcinoma classification. Robert A. Soslow, MD

Inherited Ovarian Cancer Diagnosis and Prevention

Atypical Hyperplasia/EIN

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE

Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation

Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions

International Society of Gynecological Pathologists Symposium 2007

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden

Germline Genetic Testing for Breast Cancer Risk

Original contribution

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose

Bases biológicas del cáncer de ovario en el siglo XXI

Article begins on next page

To discuss. Predictive Value of BRCA Histology. Tumour morphology: BRCA-1. Hereditary breast-ovarian cancer (HBOC)

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

What is the gynecologist s role in the care of BRCA previvors?

BSO, HRT, and ERT. No relevant financial disclosures

Case # 4 Low-Grade Serous Carcinoma (Macropapillary) of the Ovary Arising in an Atypical Proliferative Serous Tumor

Tumori eredofamiliari: sorveglianza di donne ad alto rischio

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran

Biology Response Controversies and Advances

GUIDE TO REVIEWING A MANUSCRIPT

Endosalpingiosis. Case report

Lavage of the uterine cavity as potential tool for diagnosis of epithelial ovarian cancer and its precursors

Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT)

Section 1. Biology of gynaecological cancers: our current understanding

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

Mucinous Tumors of the Ovary Beirut, Lebanon. Anaís Malpica, M.D. Professor Department of Pathology

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Fast Facts: Ovarian Cancer

Ovarian Clear Cell Carcinoma

Important Recent Advances in Gynaecological Pathology

X-Plain Ovarian Cancer Reference Summary

Definition of Synoptic Reporting

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer

Diagnostic problems in uterine smooth muscle tumors

Ovarian Cancer Causes, Risk Factors, and Prevention

The Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh

Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center

Management of BRCA mutation carriers

Serous Tubal Carcinogenesis: The Recent Concept of Origin of Ovarian, Primary Peritoneal and Fallopian Tube High-Grade Serous Carcinoma

NAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary

Screening and prevention of ovarian cancer

Department of Pathology, Magee Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213, USA 2

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG

3 cell types in the normal ovary

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Mousa. Najat kayed &Renad Al-Awamleh. Nizar Alkhlaifat

Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD

BRCA mutation carrier patient: How to manage?

Borderline tumors. Borderline tumors. Serous borderline tumor are NOT benign. Low grade serous carcinoma: pathogenesis. Serous carcinoma: pathogenesis

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

Hereditary Gynecologic Cancer 15 Years of Progress

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

Ovarian Cancer Includes Epithelial, Fallopian Tube, Primary Peritoneal Cancer, and Ovarian Germ Cell Tumors

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

Eligibility criteria for prophylactic treatment allowance

Partners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014

The Origin of Pelvic Low-Grade Serous Proliferative Lesions

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Case presentation 04/13/2017. Genomic/morphological classification of endometrial carcinoma

Christine Herde, MD, FACOG

Interactive Staging Bee

Genetic Studies of Dysgerminoma

OVARIAN CANCER Updates in Screening, Early Detection and Prevention

05/07/2018. Types of challenges. Challenging cases in uterine pathology. Case 1 ` 65 year old female Post menopausal bleeding Uterine Polyp

Question 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+

Role of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters

Stage 3 ovarian cancer survival rate

Patologia Molecular del Carcinoma de Ovario

CDH1 truncating alterations were detected in all six plasmacytoid-variant bladder tumors analyzed by whole-exome sequencing.

Low-grade serous neoplasia. Robert A. Soslow, MD

Stage 3 ovarian cancer survival rate

Histopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube

When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box?

Disclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%

Opportunistic Risk Reduction Salpingectomy and Ovarian Cancer

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

What You Need to Know About Ovarian Cancer

Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr

Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction

Long-Term Health Outcomes of Surgical Menopause

Borderline Ovarian Tumours. Andreas Obermair Brisbane

217 Gynecologic Familial Cancer Syndromes: What the Practicing Pathologist Needs to Know. Teri Longacre MD Ann Folkins MD

PRIMARY ADENOCARCINOMA OF THE FALLOPIAN TUBE - A CASE REPORT

Protocol for the Examination of Specimens from Patients with Carcinoma of the Fallopian Tube

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Transcription:

Stains for Tumor Classification p53 p16 WT1 HMGA2 P53 Mutations are Ubiquitous in High Grade Serous Carcinoma Source Ahmed et al Australian Ovarian Cancer Study Cancer Genome Atlas Research Network Cases TP53 mutation % mutated 123 119 96.7 316 303 96% Interpretation of p53 Immunostains Diffuse strong positive nuclear staining Missense mutation Complete absence of nuclear staining Null mutation (due to frameshift, splicing junction and nonsense mutations) Weak and patchy nuclear staining Wild type; no mutation 11

Positive total staining Negative focal weak staining Positive total lack of stain The Journal of Pathology 2010; 222: 191-198 Positive p16 Negative p16 BRCA Mutations are the Most Common Cause of Hereditary Ovarian Cancer Lifetime risk of breast cancer 56-84% in women with BRCA1 or BRCA2 mutations BRCA1-7% of ovarian cancer cases 39-63% risk of ovarian cancer by age 70 Risk greatest after 40 years of age Accounts for 70% of hereditary ovarian cancer BRCA2-2% of ovarian cancer cases 11-27% risk of ovarian cancer by age 70 Risk greatest after 50 years of age 76% diagnosed after age 60 12

BRCA Proteins Play critical roles in maintenance of genomic stability, especially via homologous recombination. BRCA1 gene on chromosome 17 (17q 12-21) Smaller, 1683 amino acids Ubiquitin ligase, impact on DNA repair, transcriptional regulation, cell-cycle progression, and meiotic sex chromosome inactivation. BRCA2 gene on chromosome 13 (13q 12-13) Larger, 3,418 amino acids Integral component of homologous recombination machinery Altered pathways in High Grade Serous Carcinoma D Bell et al. Nature 474, 609-615 (2011) Cancer Genome Atlas Research Network 13

Figure. Kaplan-Meier Estimates of Cumulative Survival According to BRCA1/2 Status Bolton, K. L. et al. JAMA 2012;307:382-389 Copyright restrictions may apply. Can pathologists recognize BRCA associated cancers by their histologic appearance? Histologic Features of BRCA1 Associated Carcinomas Fujiwara Serous or undifferentiated Marked atypia Giant bizarre nuclei Prominent TIL (>40/hpf) Numerous mitotic figures All 5 compatible with BRCA1 3 or 4 possibly compatible with BRCA1 0-2 not compatible with BRCA1 Soslow Serous SET features (solid, pseudoendometrioid, transitional) Geographic necrosis Prominent TIL (>37/ hpf) High mitotic rate (>51/10 hpf) BRCA related if 2 features BRCA indeterminate if 1 feature Not BRCA if no features Mod Pathol 2012; 25(4): 625-636 14

Pages 1609-1615 Pages 1616-1622 -Mean age of ovarian cancer diagnosis 51, 54% diagnosed before age 50 -Prophylactic bilateral salpingo-oophorectomy (risk reducing salpingooophorectomy) reduces risk of ovarian cancer by 95% and risk of breast cancer by 50% Cross sections of the rest of the tube like a sausage Longitudinally block the fimbriated end of the tube 15

Sectioning of RRSO Specimens Case 4 Tubal Intraepithelial Carcinoma in an RRSO 1. Nuclei are enlarged, hyperchromatic, pleomorphic. 2. Nuclei are stratified, tufted. 3. Loss of polarity. 4. Mitotic figures, apoptotic bodies present. 5. Usually p53+, high percentage stain for MIB-1. 6. No invasion. 16

Pathology Review of 150 RRSO Cases Performed at UCSF Case Ovary FT Side Size Met Stage FU 1 Serous Neg Uni 0.9 mm None IA PP, 7y 2 Neg Serous, TIC, I Uni 8.2 mm None IA-0 NED, 7y 3 Neg Serous, TIC, F Uni 2.0 mm + Cyto IC NED, 4y 4 CIS, surface TIC, F Uni 1.0 mm None 0 NED, 3y 5 Serous Neg Bi 11, 3 mm LN IIIC AWT, 2y 6 Neg TIC, F Uni 1 mm None 0 NED, 1.5y 7 Neg TIC, F Uni 2 mm + Cyto IC NED, 1y 8 Neg TIC, I Uni 2 mm None 0 R 9 Serous Serous, TIC, F Ovary Bi FT Uni Ovary 13, 5.5 mm FT 6 mm LN + Cyto Positive findings in about 6% of patients IIIC R STIC Could be a Precursor of Pelvic High Grade Serous Carcinoma Kindleberger et al, 2007 Przybycin et al, 2010 Kuhn et al, 2012 75% of high grade pelvic serous carcinomas associated with a STIC 60% of high grade pelvic serous carcinomas associated with a STIC 29 cases with a STIC and high grade pelvic serous carcinoma Same p53 mutation in STIC and ovarian carcinoma in 5/5 tested (100%) Same p53 mutation in 27/29 (93%) 17

Kindelberger DW et al. Am J Surg Pathol 2007;31:161-169 Findings in the Left Fallopian Tube of CTTR case 1 Serous Carcinoma Serous Tubal Intraepithelial Carcinoma 18

p53 p16 CASE 1 Diagnosis Pelvic High Grade Serous Carcinoma, Possibly Originating in the Fallopian Tube Case 2 The patient was a 53 year old woman. No clinical history was provided. She was treated by hysterectomy and BSO, with staging Tumor involved both ovaries, and there was seeding of the omentum, cul-desac peritoneum, and uterine serosa, and involvement of an omental lymph node 19